Two-Year Toxicity and Efficacy of Carbon Ion Radiotherapy in the Treatment of Localized Prostate Cancer: A Single-Centered Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Feb 28

PMID 35223457

Authors

Ping Li

Zhengshan Hong

Yongqiang Li

Shen Fu

Qing Zhang

Affiliations

Soon will be listed here.

Abstract

Background: We aimed at determining the safety and feasibility of spot-scanning carbon ion radiotherapy (CIRT) for patients with localized prostate cancer.

Methods: We enrolled 118 patients with localized prostate cancer who underwent treatment with spot-scanning CIRT at the Shanghai Proton and Heavy Ion Center (SPHIC) from January 2016 to December 2020. The dose was gradually increased from relative biological effectiveness (RBE)-weighted dose (D) = 59.2-65.6 Gy in 16 fractions. The primary endpoint was the occurrence of acute and late toxicities, while the secondary endpoints were biochemical relapse-free survival (bRFS), distant metastasis-free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS).

Results: The median follow-up time was 30.2 months (4.8-62.7 months). Acute grade 1 and 2 genitourinary (GU) toxicities were 15.3% and 18.6%, while acute grade 1 and 2 gastrointestinal (GI) toxicities were 2.5% and 0%, respectively. Late grade 1 and 2 GU toxicities were 4.2% and 1.7%, respectively. No late GI toxicity was observed. Moreover, there were no cases of severe acute or late toxicity (≥ grade 3). No significant association were observed between the factors and the acute GU toxicities, except for clinical target volume (CTV) (p = 0.031) on multivariate analysis. The 2-year bRFS, DMFS, PCSS, and OS were 100%, 100%, 100%, and 98.8%, respectively.

Conclusion: The 2-year outcomes were encouraging, providing additional and useful information on the feasibility and safety of spot-scanning CIRT for treating prostate cancer. Thus, we recommend long-term follow-up and prospective multicentered studies to reinforce the role of CIRT in the management of localized prostate cancer.

Citing Articles

A deep learning model for predicting the modified micro-dosimetric kinetic model-based dose and the dose-averaged linear energy transfer for prostate cancer in carbon ion therapy.

Zhang L, Wang W, Li P, Zhang Q, Han R Phys Imaging Radiat Oncol. 2024; 32:100671.

PMID: 39624391 PMC: 11609691. DOI: 10.1016/j.phro.2024.100671.

Correlation between dose-volume parameters and rectal bleeding after 12 fractions of carbon ion radiotherapy for prostate cancer.

Ono T, Sato H, Miyasaka Y, Hagiwara Y, Yano N, Akamatsu H World J Radiol. 2024; 16(7):256-264.

PMID: 39086610 PMC: 11287435. DOI: 10.4329/wjr.v16.i7.256.

Dosimetric comparison between stereotactic body radiotherapy and carbon-ion radiation therapy for prostate cancer.

Huang H, Gao X, Li Q, Ma X, Du L, Sun P Quant Imaging Med Surg. 2023; 13(10):6965-6978.

PMID: 37869307 PMC: 10585578. DOI: 10.21037/qims-23-340.

References

Cox J, Stetz J, Pajak T . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-6. DOI: 10.1016/0360-3016(95)00060-C. View

Molinelli S, Magro G, Mairani A, Matsufuji N, Kanematsu N, Inaniwa T . Dose prescription in carbon ion radiotherapy: How to compare two different RBE-weighted dose calculation systems. Radiother Oncol. 2016; 120(2):307-12. DOI: 10.1016/j.radonc.2016.05.031. View

Takakusagi Y, Katoh H, Kano K, Anno W, Tsuchida K, Mizoguchi N . Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer. Radiat Oncol. 2020; 15(1):127. PMC: 7254700. DOI: 10.1186/s13014-020-01575-7. View

Li Y, Li P, Hsi W, Hong Z, Fu S, Zhang Q . Normal tissue complication probability (NTCP) models of acute urinary toxicity (AUT) following carbon ion radiotherapy (CIRT) for prostate cancer. Radiother Oncol. 2020; 156:69-79. DOI: 10.1016/j.radonc.2020.12.009. View

Dearnaley D, Jovic G, Syndikus I, Khoo V, Cowan R, Graham J . Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014; 15(4):464-73. DOI: 10.1016/S1470-2045(14)70040-3. View

Kalbasi A, Li J, Berman A, Swisher-McClure S, Smaldone M, Uzzo R . Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer. JAMA Oncol. 2015; 1(7):897-906. DOI: 10.1001/jamaoncol.2015.2316. View

Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth M, Nussen S . Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 70(1):83-9. DOI: 10.1016/j.ijrobp.2007.05.051. View

Habl G, Uhl M, Sonja Katayama , Kessel K, Hatiboglu G, Hadaschik B . Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial. Int J Radiat Oncol Biol Phys. 2016; 95(1):435-443. DOI: 10.1016/j.ijrobp.2016.02.025. View

Iannalfi A, DIppolito E, Riva G, Molinelli S, Gandini S, Viselner G . Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy. Neuro Oncol. 2020; 22(9):1348-1358. PMC: 7523440. DOI: 10.1093/neuonc/noaa067. View

10.

Wang W, Huang Z, Sheng Y, Zhao J, Shahnazi K, Zhang Q . RBE-weighted dose conversions for carbon ionradiotherapy between microdosimetric kinetic model and local effect model for the targets and organs at risk in prostate carcinoma. Radiother Oncol. 2019; 144:30-36. DOI: 10.1016/j.radonc.2019.10.005. View

11.

Takagi M, Demizu Y, Nagano F, Terashima K, Fujii O, Jin D . Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study. Radiat Oncol. 2018; 13(1):232. PMC: 6260885. DOI: 10.1186/s13014-018-1173-0. View

12.

Tinganelli W, Durante M . Carbon Ion Radiobiology. Cancers (Basel). 2020; 12(10). PMC: 7603235. DOI: 10.3390/cancers12103022. View

13.

Nomiya T, Tsuji H, Kawamura H, Ohno T, Toyama S, Shioyama Y . A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate cancer: A report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS). Radiother Oncol. 2016; 121(2):288-293. DOI: 10.1016/j.radonc.2016.10.009. View

14.

Michalski J, Moughan J, Purdy J, Bosch W, Bruner D, Bahary J . Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018; 4(6):e180039. PMC: 5885160. DOI: 10.1001/jamaoncol.2018.0039. View

15.

Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley W, Sokol G . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65(4):965-74. DOI: 10.1016/j.ijrobp.2006.04.029. View

16.

Schulz-Ertner D, Tsujii H . Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007; 25(8):953-64. DOI: 10.1200/JCO.2006.09.7816. View

17.

Fossati P, Matsufuji N, Kamada T, Karger C . Radiobiological issues in prospective carbon ion therapy trials. Med Phys. 2018; 45(11):e1096-e1110. DOI: 10.1002/mp.12506. View

18.

Shioyama Y, Tsuji H, Suefuji H, Sinoto M, Matsunobu A, Toyama S . Particle radiotherapy for prostate cancer. Int J Urol. 2014; 22(1):33-9. DOI: 10.1111/iju.12640. View

19.

Fossati P, Molinelli S, Matsufuji N, Ciocca M, Mirandola A, Mairani A . Dose prescription in carbon ion radiotherapy: a planning study to compare NIRS and LEM approaches with a clinically-oriented strategy. Phys Med Biol. 2012; 57(22):7543-54. DOI: 10.1088/0031-9155/57/22/7543. View

20.

Ishikawa H, Tsuji H, Kamada T, Hirasawa N, Yanagi T, Mizoe J . Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 66(4):1084-91. DOI: 10.1016/j.ijrobp.2006.06.056. View